These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 11953330)

  • 1. The genetic jigsaw of inflammatory bowel disease.
    Watts DA; Satsangi J
    Gut; 2002 May; 50 Suppl 3(Suppl 3):III31-6. PubMed ID: 11953330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
    Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Polymorphism of the microsatellites and tumor necrosis factor genes in chronic inflammatory bowel diseases].
    Heresbach D; Ababou A; Bourienne A; Alizadeh M; Quelvennec E; Pagenault M; Dabadie A; Berre NH; Campion JP; Launois B; Gosselin M; Genetet B; Bretagne JF; Semana G
    Gastroenterol Clin Biol; 1997; 21(8-9):555-61. PubMed ID: 9587492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics of inflammatory bowel disease.
    Satsangi J; Parkes M; Jewell DP; Bell JI
    Clin Sci (Lond); 1998 May; 94(5):473-8. PubMed ID: 9682668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetics of inflammatory bowel disease: from bench to bedside?
    Satsangi J
    Acta Odontol Scand; 2001 Jun; 59(3):187-92. PubMed ID: 11501890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
    Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC
    Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics of inflammatory bowel disease: progress and prospects.
    Mathew CG; Lewis CM
    Hum Mol Genet; 2004 Apr; 13 Spec No 1():R161-8. PubMed ID: 14764625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy].
    Ochsenkühn T; Sackmann M; Göke B
    Radiologe; 2003 Jan; 43(1):1-8. PubMed ID: 12552369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab.
    Urcelay E; Mendoza JL; Martinez A; Fernandez L; Taxonera C; Diaz-Rubio M; de la Concha EG
    World J Gastroenterol; 2005 Feb; 11(8):1187-92. PubMed ID: 15754402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The genetic basis of inflammatory bowel disease unravelled by genetic association studies].
    Visschedijk MC; Festen EA; Wijmenga C; Weersma RK
    Ned Tijdschr Geneeskd; 2009; 153():A402. PubMed ID: 19900309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducing remission in inflammatory bowel disease.
    Drug Ther Bull; 2003 Apr; 41(4):30-2. PubMed ID: 12724846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging biologic therapies in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(2):66-85. PubMed ID: 15184826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenetic biomarkers in inflammatory bowel diseases: role of the IBD3 region.
    Muro M; López-Hernández R; Mrowiec A
    World J Gastroenterol; 2014 Nov; 20(41):15037-48. PubMed ID: 25386052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics of inflammatory bowel disease. A personal view on progress and prospects.
    Satsangi J; Jewell D; Parkes M; Bell J
    Dig Dis; 1998; 16(6):370-4. PubMed ID: 10207224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour necrosis factor-alpha (-308G/A) promoter polymorphism is associated with ulcerative colitis in Brazilian patients.
    Tavares M; de Lima C; Fernandes W; Martinelli V; de Lucena M; Lima F; Telles A; Brandão L; de Melo Júnior M
    Int J Immunogenet; 2016 Dec; 43(6):376-382. PubMed ID: 27528546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunology in medical practice. XXVI. Immunogenetics of chronic inflammatory bowel diseases].
    Bouma G; Peña AS
    Ned Tijdschr Geneeskd; 1999 Nov; 143(48):2414-20. PubMed ID: 10608975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent understanding of IBD pathogenesis: implications for future therapies.
    Kucharzik T; Maaser C; Lügering A; Kagnoff M; Mayer L; Targan S; Domschke W
    Inflamm Bowel Dis; 2006 Nov; 12(11):1068-83. PubMed ID: 17075348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variants in TNF-alpha but not DLG5 are associated with inflammatory bowel disease in a large United Kingdom cohort.
    Tremelling M; Waller S; Bredin F; Greenfield S; Parkes M
    Inflamm Bowel Dis; 2006 Mar; 12(3):178-84. PubMed ID: 16534418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.